ASCO 2026: Molecular Testing as a Therapeutic Determinant
The 2026 American Society of Clinical Oncology Annual Meeting, held in Chicago from May 29 to June 2, convened more than 40,000 oncology professionals in what stands as one of the most clinically and translationally significant scientific gatherings in recent years. The results presented — drawn from phase 2 and 3 trials across highly diverse therapeutic areas — converge on an increasingly consolidated paradigm: molecular characterization of the tumor is not an ancillary diagnostic tool, but the indispensable prerequisite for access to next-generation therapies.
The following is a curated selection of highlights from the most clinically relevant presentations at ASCO 2026, covering key tumor types in which biomarker-driven therapeutic advances are reshaping standard of care.
Gastrointestinal Cancers
1- RAS(ON) Inhibition Redefines Second-Line Pancreatic Cancer
Tumor: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — 2nd line
Therapy: Daraxonrasib (RAS[ON] multi-selective inhibitor) vs. standard chemotherapy
Biomarker: RAS mutation — pan-RAS activity (KRAS, NRAS, HRAS)
Testing: Tumor molecular profiling — NGS or qPCR-based RAS mutation analysis
- Phase 3 RASolute 302: daraxonrasib reduced risk of death by 60% vs chemotherapy (OS 13.2 vs 6.7 months).
- Efficacy observed regardless of specific RAS variant, supporting comprehensive pan-RAS testing rather than variant-specific selection.
- New standard of care for 2L mPDAC — broad RAS testing becomes clinically essential.
Wolpin BM, et al. Daraxonrasib vs chemotherapy in previously treated mPDAC: primary and final analysis from the phase 3 RASolute 302 study. Abstract LBA5. ASCO 2026; Chicago.
2- MEK Inhibition in First-Line Pancreatic Cancer
Tumor: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — 1st line
Therapy: Atebimetinib (MEK1/2 inhibitor) + modified gemcitabine/nab-paclitaxel
Biomarker: RAS/MAPK pathway activation
Testing: MAPK pathway biomarker profiling — RAS/RAF mutation analysis
- Phase 2a (n=50): promising activity across ORR, DCR, PFS and OS with favorable tolerability.
- MEK inhibition enters frontline PDAC — pathway profiling required for patient selection.
Vu P, Chung V, Hosein PJ, et al. Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer. Abstract 4013. ASCO 2026; Chicago.
3- FGFR2 Inhibition Confirmed as First-Line Standard in Cholangiocarcinoma
Tumor: Unresectable/Metastatic Cholangiocarcinoma
Therapy: Pemigatinib (Pemazyre) vs. gemcitabine + cisplatin
Biomarker: FGFR2 gene rearrangement / fusion
Testing: RNA fusion NGS panel or FISH — FGFR2 rearrangement detection mandatory before treatment
- Phase 3 FIGHT-302: pemigatinib achieved superior PFS (8.3 vs 6.8 months) exclusively in FGFR2-rearranged patients.
- FGFR2 testing is non-negotiable for any frontline CCA treatment decision.
Bekaii-Saab TS, Melisi D, Wilmink H, et al. Pemigatinib for unresectable advanced or metastatic cholangiocarcinoma with FGFR2 rearrangement: results from the confirmatory phase 3 FIGHT-302 trial. Abstract 4017. ASCO 2026; Chicago.
4- HER2+ Gastroesophageal Adenocarcinoma: Survival Benefit Independent of PD-L1
Tumor: HER2-positive Gastroesophageal Adenocarcinoma — 1st line
Therapy: Zanidatamab + tislelizumab + chemotherapy vs. trastuzumab + chemotherapy
Biomarker: HER2 overexpression/amplification (primary); PD-L1 expression (secondary)
Testing: IHC/FISH for HER2 status; IHC for PD-L1 — dual biomarker assessment
- HERIZON-GEA-01: PFS 12.4 vs 8.1 months and OS 26.4 vs 19.2 months with zanidatamab combination.
- Benefit maintained regardless of PD-L1 expression level — HER2 remains the primary selection criterion.
Rha SY, Shitara K, Lin S, et al. Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive mGEA: PD-L1 subgroup analysis from HERIZON-GEA-01. J Clin Oncol. 2026;44(suppl 16):4010.
5- ctDNA Dynamics Guide Adjuvant Chemotherapy Duration in Colorectal Cancer
Tumor: Resected Colorectal Cancer (stage I–IV)
Therapy: Adjuvant chemotherapy (ACT) — duration optimization
Biomarker: Circulating tumor DNA (ctDNA) — MRD dynamics at 3 months
Testing: Liquid biopsy — ctDNA quantification (tumor-informed ddPCR or NGS-based)
- CIRCULATE-Japan GALAXY (n=1,028): ctDNA dynamics at ~3 months meaningfully stratify recurrence risk.
- Sustained ctDNA negativity: no additional benefit from extended ACT. Rising ctDNA: high relapse risk requiring intensification.
- ctDNA monitoring transforms adjuvant CRC management — liquid biopsy enters routine clinical decision-making.
Oki E, Yamamoto H, Bando H, et al. Informing optimal duration of adjuvant chemotherapy in resected stage I-IV colorectal cancer based on early ctDNA dynamics. J Clin Oncol. 2026;44(suppl 16):3501.
Breast Cancer
6-Genomic Profiling Spares Thousands from Unnecessary Chemotherapy
Tumor: Early-stage ER+/HER2− Breast Cancer
Therapy: Hormone therapy alone (genomically selected low-risk patients)
Biomarker: Prosigna genomic risk score (PAM50-based)
Testing: Tumor gene expression profiling — Prosigna/PAM50 assay
- Phase 3 OPTIMA (n=4,429): ~68% of chemotherapy-eligible patients had low genomic risk.
- In low-risk patients: 5-year recurrence-free survival 93.6% with hormone therapy alone vs 94.8% with chemotherapy — statistically equivalent outcomes.
- Genomic testing recommended for all eligible early ER+/HER2− BC — up to 68% can safely avoid chemotherapy.
Stein R, et al. OPTIMA: a randomised, phase 3 trial of genomic test-directed chemotherapy de-escalation in early breast cancer. ASCO 2026; Chicago.
7- TNBC: Pembrolizumab Shows Durable 7-Year Survival Benefit
Tumor: High-risk Early-stage Triple-Negative Breast Cancer (TNBC)
Therapy: Pembrolizumab + neoadjuvant chemotherapy → adjuvant pembrolizumab
Biomarker: TNBC subtype (ER−/PR−/HER2−)
Testing: Full IHC receptor panel (ER, PR, HER2) — TNBC classification is the eligibility gateway
- KEYNOTE-522 final analysis (7-year follow-up): >85% alive with pembrolizumab vs 77% with chemotherapy alone.
- Long-term benefit is sustained and durable — TNBC subtyping is the treatment selection criterion.
Schmid P, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis from the phase 3 KEYNOTE-522 study. J Clin Oncol. 2026;44(suppl 16):abstr 507.
Sarcoma
8- First Positive Phase 3 Trial in Dedifferentiated Liposarcoma
Tumor: Advanced Dedifferentiated Liposarcoma (DDLPS)
Therapy: Abemaciclib (Verzenio, CDK4/6 inhibitor) vs. placebo
Biomarker: CDK4 amplification / MDM2 amplification — hallmark of DDLPS
Testing: FISH or NGS for CDK4/MDM2 amplification — pathognomonic for DDLPS diagnosis
- Phase 3 SARC041: PFS 9.7 vs 1.5 months — the first-ever positive Phase 3 trial in this disease.
- CDK4 amplification, a defining molecular feature of DDLPS, is the biological rationale for CDK4/6 inhibition.
- Historic milestone: CDK4 molecular testing gains clinical significance beyond breast cancer.
Dickson MA, et al. SARC041: a phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Abstract LBA2. ASCO 2026; Chicago.
Prostate Cancer
9- Perioperative Intensification Transforms High-Risk Localized Disease
Tumor: High-risk Localized/Locally Advanced Prostate Cancer
Therapy: Apalutamide (Erleada) + ADT — perioperative (6 months pre/post radical prostatectomy)
Biomarker: High-risk clinicopathological features (high Gleason, high PSA, pT3/N1)
Testing: PSA testing, Gleason scoring (biopsy), clinical staging — risk stratification is the selection tool
- Phase 3 PROTEUS (n=2,109, 18 countries): patients 9× more likely to achieve minimal residual disease at surgery (8.9% vs 1.0%).
- Risk of metastasis/death reduced by 20%; median time to additional therapy >6 years.
- PSA/Gleason risk profiling becomes the gateway for perioperative treatment intensification.
Taplin ME, et al. Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized or locally advanced prostate cancer: final analysis of the PROTEUS phase 3 study. Abstract LBA1. ASCO 2026; Chicago.
Lung Cancer
10-First Adjuvant Therapy for RET Fusion-Positive NSCLC
Tumor: Early-stage NSCLC — post-surgery/radiation
Therapy: Selpercatinib (Retevmo) adjuvant vs. placebo
Biomarker: RET gene fusion (1–2% of NSCLC)
Testing: RNA fusion NGS panel or FISH — RET fusion detection required before adjuvant decision
- Phase 3 LIBRETTO-432: 83% reduction in risk of recurrence/death. At 2 years: 91.5% recurrence-free vs 61.1% with placebo.
- RET fusion testing is now mandatory in the resectable NSCLC workup — immediately practice-changing.
Goldman JW, et al. LIBRETTO-432: adjuvant selpercatinib in RET fusion-positive non-small cell lung cancer. Abstract LBA3. ASCO 2026; Chicago.
11- PD-L1 × VEGF Bispecific Antibody Shows 70% ORR in First-Line NSCLC
Tumor: Treatment-naive Advanced NSCLC
Therapy: Pumitamig (BNT327/BMS-986545) — PD-L1 × VEGF-A bispecific antibody + chemotherapy
Biomarker: PD-L1 expression; VEGF-A pathway activation
Testing: IHC for PD-L1; dual biomarker profiling expected to refine Phase 3 patient selection
- Phase 2 ROSETTA Lung-02: ORR 70%, DCR 100%. Phase 3 vs pembrolizumab + chemotherapy ongoing.
- Dual PD-L1/VEGF targeting represents a next-generation approach where combined biomarker profiling may optimize selection.
Peters S, et al. Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig + chemotherapy in 1L NSCLC. J Clin Oncol. 2026;44(suppl 16):abstr 8513.
Melanoma
12- mRNA Neoantigen Vaccine Sustains 5-Year Protection in Resected Melanoma
Tumor: High-risk Resected Melanoma
Therapy: Intismeran (individualized mRNA neoantigen vaccine) + pembrolizumab
Biomarker: Tumor-specific neoantigens — unique to each patient’s tumor
Testing: Tumor WES/WGS + RNA sequencing for individualized neoantigen identification
- KEYNOTE-942 5-year update: 49% reduction in recurrence risk, 62% reduction in distant metastasis risk vs pembrolizumab alone.
- 7 of 8 vaccine responders alive at 6+ years. Benefit sustained and durable over time.
- Individualized neoantigen profiling enables vaccine-based precision oncology — a new paradigm for high-risk melanoma.
Carlino MS, et al. Individualized neoantigen therapy intismeran autogene plus pembrolizumab in resected melanoma: 5-year update of the KEYNOTE-942 study. J Clin Oncol. 2026;44(suppl 16):abstr 9500.
Hematologic Oncology
13-BTK Inhibition in CLL: 78-Month Data Confirms Long-Term Control
Tumor: Chronic Lymphocytic Leukemia / SLL — 1st line (incl. del(17p))
Therapy: Zanubrutinib (Brukinsa, BTK inhibitor) vs. bendamustine + rituximab
Biomarker: IGHV mutation status; del(17p) / TP53 mutation
Testing: FISH for del(17p); IGHV mutation status (Sanger/NGS); TP53 sequencing — comprehensive CLL molecular workup
- SEQUOIA 78-month data: PFS 71.8% with zanubrutinib vs 31% with BR. In IGHV-mutated patients: 81.8% vs 45.1%.
- Benefit confirmed across all molecular subgroups, including high-risk del(17p).
- Molecular subtyping (IGHV, del17p, TP53) is essential to quantify benefit magnitude and guide frontline CLL therapy.
Lun Tam, et al. SEQUOIA 5-year follow-up: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive CLL/SLL. J Clin Oncol. 2026;44(suppl 16):abstr 7011.
The data presented at ASCO 2026 confirm that precision oncology has reached a level of clinical maturity that demands a structural reassessment of diagnostic pathways. From minimal residual disease monitoring via ctDNA in colorectal cancer, to the identification of RET fusions in resectable NSCLC, to individualized neoantigen profiling in melanoma. The timely integration of molecular testing into multidisciplinary oncology pathways is no longer an ancillary recommendation — it is the enabling condition for access to the most effective therapies currently available.